Please use this identifier to cite or link to this item:
Title: 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model
Author: Slater, Kayleigh
Bosch, Rosa
Smith, Kaelin Francis
Jahangir, Chowdhury Arif
Garcia Mulero, Sandra
Rahman, Arman
O’Connell, Fiona
Piulats, Josep M.
O’Neill, Valerie
Horgan, Noel
Coupland, Sarah E.
O’Sullivan, Jacintha
Gallagher, William M.
Villanueva Garatachea, Alberto
Kennedy, Breandán N.
Keywords: Melanoma
Issue Date: 9-Jan-2023
Publisher: Frontiers Media SA
Abstract: Uveal melanoma (UM) is an intraocular cancer with propensity for liver metastases. The median overall survival (OS) for metastatic UM (MUM) is 1.07 years, with a reported range of 0.84-1.34. In primary UM, high cysteinyl leukotriene receptor 1 (CysLT(1)) expression associates with poor outcomes. CysLT(1) antagonists, quininib and 1,4-dihydroxy quininib, alter cancer hallmarks of primary and metastatic UM cell lines in vitro. Here, the clinical relevance of CysLT receptors and therapeutic potential of quininib analogs is elaborated in UM using preclinical in vivo orthotopic xenograft models and ex vivo patient samples. Immunohistochemical staining of an independent cohort (n = 64) of primary UM patients confirmed high CysLT(1) expression significantly associates with death from metastatic disease (p = 0.02; HR 2.28; 95% CI 1.08-4.78), solidifying the disease relevance of CysLT(1) in UM. In primary UM samples (n = 11) cultured as ex vivo explants, 1,4-dihydroxy quininib significantly alters the secretion of IL-13, IL-2, and TNF-alpha. In an orthotopic, cell line-derived xenograft model of MUM, 1,4-dihydroxy quininib administered intraperitoneally at 25 mg/kg significantly decreases ATP5B expression (p = 0.03), a marker of oxidative phosphorylation. In UM, high ATP5F1B is a poor prognostic indicator, whereas low ATP5F1B, in combination with disomy 3, correlates with an absence of metastatic disease in the TCGA-UM dataset. These preclinical data highlight the diagnostic potential of CysLT(1) and ATP5F1B in UM, and the therapeutic potential of 1,4-dihydroxy quininib with ATP5F1B as a companion diagnostic to treat MUM.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Medicine, 2023, vol. 9, num. 1036322
Related resource:
ISSN: 2296-858X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
fmed-09-1036322.pdf4.08 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons